Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioLiberty

Explore full profile

Soft robotic glove for stroke rehabilitation therapy

Edinburgh, United KingdomFounded 2020Health Tech & Medtech
Valuation $25–50M Last recorded · 2026
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for BioLiberty and the history behind them.

About BioLiberty

BioLiberty is a medical technology company founded in 2020 by Rowan Armstrong, Ross O'Hanlon, Shea Quinn, and Conan Bradley. The founders, alumni of the University of Edinburgh's MEng program, were inspired to start the company after one of them witnessed a family member with multiple sclerosis struggle with hand weakness. The firm is headquartered in Edinburgh, Scotland, at the National Robotarium, with a U.S. base in Boston.

The company develops soft robotic wearables and gamified digital therapy platforms to assist individuals with mobility-limiting conditions, initially focusing on stroke survivors. Its flagship product is the "Lifeglov," a soft robotic glove that assists patients with opening and closing their hand, combined with a digital therapy platform that provides tailored exercises and tracks metrics like range of motion and force. This system, known as Lifehub Clinic, is designed for use in clinical settings to deliver high-intensity, engaging therapy. It is powered by air and uses AI algorithms to provide controlled assistance calibrated to the patient's ability, with the goal of promoting neuroplasticity. The accompanying "Lifemind" software suite gives therapists insights into patient progress and will use AI to personalize treatments and streamline documentation for reimbursement.

BioLiberty's business model targets rehabilitation clinics and healthcare professionals, providing tools for remote patient management and improved outcomes. The company generates revenue through the sale of its FDA-registered Lifehub and Lifeglov products. Having secured significant funding, including a £2.2 million round led by Archangels and a subsequent £435,000 from Innovate UK, the company is focused on commercial expansion in the U.S. and UK markets and has initiated clinical studies with partners like the Mount Sinai Health System. While the initial focus is on upper-limb therapy for stroke patients, BioLiberty plans to expand its technology to other conditions and lower-limb applications.

Source: Dealroom company data

At a glance

Founded
2020
Headquarters
Edinburgh, United Kingdom
Sector
Health Tech & Medtech

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • CO-FOUNDERS
  • Catalyst Belfast Fintech Hub
  • Scottish Enterprise Growth Investments
  • Archangels
  • Eos Advisory
  • Hanna Capital SEZC
  • Edinburgh Innovations

Series A4 investors entered at this stage

  • University of Edinburgh
  • Scottish National Investment Bank
  • Old College Capital
  • The Conduit Connect
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇬🇧 United Kingdom67.9%
🇺🇸 United States32.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioLiberty on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioLiberty on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.